Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Index
RUT
Market Cap
3.38B
Enterprise Value
2.77B
Income
-435.21M
Sales
26.31M
Book/sh
4.25
Cash/sh
8.42
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
252
IPO
Jun 18, 2014
P/E
-
Forward P/E
-
PEG
-
P/S
128.62
P/B
7.01
P/C
3.54
P/FCF
-
EV/EBITDA
-
EV/Sales
105.24
Quick Ratio
14.46
Current Ratio
14.46
Debt/Eq
0.42
LT Debt/Eq
0.42
Option/Short
Yes / Yes
EPS (ttm)
-4.18
EPS next Y
-2.09
EPS next Q
-0.72
EPS this Y
-6.90%
EPS next Y
41.07%
EPS next 5Y
-
EPS past 3/5Y
6.35% 36.07%
Sales past 3/5Y
241.95% 132.18%
EPS Y/Y TTM
-18.22%
Sales Y/Y TTM
-62.83%
EPS Q/Q
-110.97%
Sales Q/Q
-63.51%
Insider Own
6.12%
Insider Trans
-0.20%
Inst Own
117.25%
Inst Trans
1.66%
ROA
-54.20%
ROE
-80.32%
ROIC
-52.87%
Gross Margin
90.77%
Oper. Margin
-1781.38%
Profit Margin
-1654.21%
SMA20
12.07%
SMA50
30.22%
SMA200
38.35%
Trades
Shs Outstand
113.53M
Shs Float
106.61M
52W High
34.29 -13.09%
52W Low
13.18 126.10%
Volatility
4.58% 5.75%
ATR (14)
1.37
RSI (14)
69.34
Beta
1.02
Rel Volume
0.00
Avg Volume
2.09M
Volume
0
Perf Week
-1.29%
Perf Month
56.59%
Perf Quarter
24.53%
Perf Half Y
85.09%
Perf YTD
-4.24%
Perf Year
3.58%
Perf 3Y
96.05%
Perf 5Y
58.68%
Perf 10Y
-64.20%
Prev Close
29.80
Price
29.80
Change %
0.00%
Consensus
Strong Buy
Avg. Price Target
$42.50
Implied Upside
+42.6%
Analysts16incl. previous ratings
Rating Distribution14 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jun 29, 2026Upgrade
WFC logoWWells Fargo
Equal Weight → Overweight$31+4.0%
Dec 10, 2025Reiterated
WWedbush
Outperform$42 → $47+57.7%
Dec 03, 2025Initiated
WWilliam Blair
Outperform
Nov 24, 2025Initiated
TFC logoTTruist
Buy
Aug 25, 2025Resumed
JEF logoJJefferies
Buy$44+47.7%
Dec 19, 2024Downgrade
WFC logoWWells Fargo
Overweight → Equal Weight$37 → $27-9.4%
Nov 25, 2024Initiated
TD logoTTD Cowen
Buy
Sep 11, 2024Reiterated
NNeedham
Buy$30 → $38+27.5%
Jun 11, 2024Initiated
WWolfe Research
Outperform$29-2.7%
Jun 06, 2024Initiated
GS logoGGoldman
Buy$23-22.8%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tousignant JenniferChief Legal OfficerAug 19 '26Option Exercise14.4110,000144,10010,000Aug 20 08:05 PM
Tousignant JenniferChief Legal OfficerAug 19 '26Sale24.5014,212348,1940Aug 20 08:05 PM
Tousignant JenniferOfficerAug 19 '26Proposed Sale24.5014,212348,194Aug 19 02:30 PM
Tripuraneni RadhikaChief Medical OfficerAug 14 '26Option Exercise13.2140,000528,40040,000Aug 18 05:34 PM
Fairmount Funds Management LLCDirectorMay 11 '26Buy17.001,176,47019,999,9905,090,928May 13 04:31 PM
Beetham Thomas W.OfficerMar 04 '26Proposed Sale30.193,04892,004Mar 04 04:29 PM
Tousignant JenniferOfficerMar 04 '26Proposed Sale30.191,67550,560Mar 04 04:25 PM
Harmon SethOfficerMar 04 '26Proposed Sale30.192,03161,306Mar 04 04:20 PM
Mahoney Stephen F.OfficerMar 04 '26Proposed Sale30.197,408223,610Mar 04 04:10 PM
Tousignant JenniferChief Legal OfficerDec 31 '25Sale31.162,27270,7960Jan 02 05:25 PM
Tousignant JenniferOfficerDec 31 '25Proposed Sale31.162,27270,796Dec 31 12:24 PM
Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves' disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.
MBAMr. Stephen F. Mahoney J.D.
Chief Financial OfficerMr. Seth Harmon
MBAMr. Thomas W. Beetham J.D.
Chief Legal Officer & Corporate SecretaryMs. Jennifer Tousignant J.D.
M.P.H.Dr. Radhika Tripuraneni M.D.